Research Roundup: Prognostic biomarkers in cancer

January 21, 2021

Many of our cancer antibodies are used in cutting-edge research to identify new prognostic markers in different cancers.

Learn More

Topics:

biomarkers / Oncology / atlasantibodies / blog / ResearchRoundup

Interview with a scientist: traffic jams at the nuclear pores.

October 06, 2020

Dysfunctional nuclear-cytoplasmic trafficking of RNA binding proteins might contribute to neurological disorders. For this blog post we spoke with Dr. Rita Sattler.She employs human patient-derived induced pluripotent stem cells to elucidate the nuclear-cytoplasmic trafficking mechanisms in neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Learn More

Topics:

Antibody Validation / Immunohistochemistry / interview / atlasantibodies

Interview with a scientist: drug repurposing in oncology

August 18, 2020

Drug repurposing is the strategy of using existing drugs originally developed for a specific disease to treat other diseases. Today we spoke with Dr. Joanna Zawacka-Pankau, PhD in biochemistry. We asked her about her research efforts in drug repurposing to treat cancer.

Learn More

Topics:

Antibody Validation / Oncology / interview / atlasantibodies / drugrepurposing

Now I see you: the imaging toolbox that improves the detection of primary ciliary dyskinesia

June 30, 2020

Ciliary motility is essential for moving fluids and particles over epithelial surfaces. Frequently, the limitations of quantitative tests and the lack of awareness delay the diagnosis of cilia diseases. In this blog post, we present antibodies- and 3D imaging-based quantitative super-resolution toolbox for the diagnosis of primary ciliary dyskinesia, a disorder of motile cilia. The researchers took part in our Explorer Program. Read on to discover what they found.

Learn More

Topics:

biomarkers / ciliopathies / imaging / atlasantibodies

1

Share this article

Sign Up

Share this blog